Abstract:Renal group, Nantong-Leicester Joint Kidney Science Institute. Introduction: Renal ischemia/reperfusion (IR) injury is one of major causes of acute kidney injury (AKI) that is lack of effective treatment. Our previous studies have revealed that EPO derived helix B surface peptide (HBSP) or cyclic HBSP (CHBP), the ligand of innate repair receptor EPOR/βcR, was renoprotective against IR injury. This study further investigated the potential synergetic renoprotection of HBSP/CHBP with small interfering RNA targeting caspase-3 (C3siRNA). Methods: Mouse renal IR injury was established in adult male C57BL/6, by blocking bilateral renal pedicles for 30 min and reperfusion for 48 h and 2 w (n = 6-9), with respective sham groups at each time point (n = 5). CHBP or HBSP at 24 nmol/kg and/or C3siRNA or negative control siRNA (NCsiRNA, 0.03 mg/kg) were administered to the IR mice. Renal function, histology and molecular biological parameters were assessed, along with genomic profile in 48-h kidneys using affymetrix gene chips. Results: At 48-h IR, CHBP or C3siRNA preserved kidney function and structure, while co-treatment of both exhibited greater preservation in kidney structure compared to single usage, as well as reduced 17 kDa active caspase-3.Microarray data revealed that 281 differentially expressed genes (DEGs) were modified by CHBP in IR kidneys, but 504 DEGs were further changed by C3siRNA treatment in contrast to the NCsiRNA control, with 3 genes commonly affected in both comparisons, according to fold change > 1.414 and P < 0.05. Some highly-dysregulated genes such as RBP4, Grem1 and Angptl2 might be new biomarker candidates. Gene Ontology analysis of biological processes showed that CHBP mainly promoted cell division, function and metabolism, and C3siRNA further modulated genes involving in renal inflammation and cell survival.At 2-w IR, co-treatment with HBSP and C3siRNA showed the additional preservation of kidney structure, as well as reduced collagen deposition in the tubulointerstitial area, compared with any single treatment.Conclusion: This proof-of-effect study indicated that simultaneously modulating caspase-3 enhanced the renoprotection of CHBP/HBSP, which might improve the short and long-term outcome of IR-induced AKI. Other highly changed candidate genes might be new biomarkers of AKI upon further validation. National Natural Science Foundation of China 81873622. References: 1. Yang C. A novel proteolysis-resistant cyclic helix B peptide ameliorates kidney ischemia reperfusion injury. Biochim Biophys Acta. 2014;1842(11):2306-17. 2. Yang C. Serum-stabilized naked caspase-3 siRNA protects autotransplant kidneys in a porcine model. Mol Ther. 2014;22(10):1817-28. 3. Wu Y. Protective Effects of HBSP on Ischemia Reperfusion and Cyclosporine A Induced Renal Injury. Clin Dev Immunol. 2013;2013:758159.

pH-induced structural changes in human serum apotransferrin. pKa values of histidine residues and N-terminal amino group determined by 1H-NMR spectroscopy.

Nanoparticle-mediated Klotho Gene Therapy Prevents Acute Kidney Injury to Chronic Kidney Disease Transition Through Regulating PPARα Signaling in Renal Tubular Epithelial Cells

Localized Delivery of shRNA against PHD2 Protects the Heart from Acute Myocardial Infarction through Ultrasound-Targeted Cationic Microbubble Destruction

Lipopolysaccharide-induced Cross-Tolerance Against Renal Ischemia–reperfusion Injury is Mediated by Hypoxia-Inducible Factor-2Α-regulated Nitric Oxide Production

Prolyl Hydroxylase 2 (PHD2) Inhibition Protects Human Renal Epithelial Cells and Mice Kidney from Hypoxia Injury

Layer‐by‐layer Assembly of Renal‐targeted Polymeric Nanoparticles for Robust Arginase‐2 Knockdown and Contrast‐induced Acute Kidney Injury Prevention

c‐Kit+ Bone Marrow Stem Cells Differentiate into Functional Cardiac Myocytes

A renal-targeted gene delivery system derived from spermidine for arginase-2 silencing and synergistic attenuation of drug-induced acute kidney injury

Potent Therapy and Transcriptional Profile of Combined Erythropoietin Derived Peptide CHBP and Caspase-3 siRNA against Kidney Ischemia/Reperfusion Injury in mice

miR-21 contributes to renal protection by targeting prolyl hydroxylase domain protein 2 in delayed ischaemic preconditioning.

Potent Therapy and Transcriptional Profile of Combined Erythropoietin-Derived Peptide Cyclic Helix B Surface Peptide and Caspase-3 Sirna Against Kidney Ischemia/Reperfusion Injury in Mice

Short-And Long-Term Synergistic Renoprotection Induced By Erythropoietin Derived Peptide And Caspase-3 Sirna Against Renal Ischemia/Reperfusion Injury In Mice

Targeted Inhibition of Pyroptosis via A Carbonized Nanoinhibitor for Alleviating Drug-Induced Acute Kidney Injury

Transcriptional Profiles in Ischemia/Reperfusion-Injured Murine Kidneys Synergistically Protected by Erythropoietin Derived Peptide CHBP and Caspase-3 siRNA

Penehyclidine hydrochloride ameliorates renal ischemia-reperfusion injury in rats.

Cholesterol‐Modified DNA Nanostructures Serve as Effective Non‐Viral Carriers for Delivering siRNA to the Kidneys to Prevent Acute Kidney Injury

Dl-3-n-butylphthalide pretreatment attenuates renal ischemia/reperfusion injury

Kim-1 Targeted Extracellular Vesicles: A New Therapeutic Platform for RNAi to Treat AKI

Protective Effect of Cardiomyocyte-Specific Prolyl-4-Hydroxylase 2 Inhibition on Ischemic Injury in a Mouse MI Model

Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation

Therapeutic Effect of Extracellular Vesicles Derived from HIF Prolyl Hydroxylase Domain Enzyme Inhibitor-Treated Cells on Renal Ischemia/Reperfusion Injury